21 results on '"Friberg, Lena E."'
Search Results
2. Impact of continuous-infusion meropenem degradation and infusion bag changes on bacterial killing of Pseudomonas aeruginosa based on model-informed translation.
- Author
-
Minichmayr, Iris K. and Friberg, Lena E.
- Abstract
• We studied whether meropenem (MEM) stability allows for continuous infusion (CI). • High- and low-dose CI regimens were simulated with a PK-PD model on P. aeruginosa. • Meropenem degradation affected plasma concentrations and bacterial load. • Infusion bag changes appeared particularly beneficial for 50 mg/mL MEM solutions. • Stability and consequently PK/PD measures improved for less concentrated infusions. Continuous infusion of meropenem has been proposed to increase target attainment in critically ill patients, although stability might limit its practical use. This study investigated the impact of meropenem degradation and infusion bag changes on the concentration-time profiles and bacterial growth and killing of P. aeruginosa given different continuous-infusion solutions. A semi-mechanistic pharmacokinetic-pharmacodynamic (PK-PD) model quantifying meropenem concentrations (C MEM) and bacterial counts of a resistant P. aeruginosa strain (ARU552, MIC = 16 mg/L) over 24 h was used to translate in vitro antibiotic effects to patients with severe infections. Concentration-dependent drug degradation of saline infusion solutions was considered using an additional compartment in the population PK model. C MEM , f T >MIC (time that concentrations exceed the MIC) and total bacterial load (B TOT) after 24 h were simulated for different scenarios (n = 144), considering low- and high-dose regimens (3000/6000 mg/day±loading dose), clinically relevant infusion solutions (20/40/50 mg/mL), different intervals of infusion bag changes (every 8/24 h, q8/24 h), and varied renal function (creatinine clearance 40/80/120 mL/min) and MIC values (8/16 mg/L). Highest deviations between changing infusion bags q8h and q24h were observed for 50 mg/mL solutions and scenarios with C MEM_24 h close to the MIC, with differences (Δ) in C MEM_24 h up to 4.9 mg/L, Δ f T >MIC ≤65.7%, and ΔB TOT_24h ≤1.1 log10 CFU/mL, thus affecting conclusions on whether bacteriostasis was reached. In summary, this study indicated that for continuous infusion of meropenem, eight-hourly infusion bag changes improved PK/PD target attainment and might be beneficial particularly for high meropenem concentrations of saline infusion solutions and for plasma concentrations in close proximity to the MIC. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS
- Author
-
Jansson, Britt, Karvanen, Matti, Cars, Otto, Plachouras, Diamantis, and Friberg, Lena E.
- Published
- 2009
- Full Text
- View/download PDF
4. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration
- Author
-
Karaiskos, Ilias, Friberg, Lena E., Galani, Lambrini, Ioannidis, Konstantinos, Katsouda, Emmanouela, Athanassa, Zoe, Paskalis, Harris, and Giamarellou, Helen
- Published
- 2016
- Full Text
- View/download PDF
5. A tool for neutrophil guided dose adaptation in chemotherapy
- Author
-
Wallin, Johan E., Friberg, Lena E., and Karlsson, Mats O.
- Subjects
- *
PHARMACODYNAMICS , *CALCULUS , *DIFFERENTIAL equations , *DRUGS - Abstract
Abstract: Chemotherapy dosing in anticancer treatment is a balancing act between achieving concentrations that are effective towards the malignancy and that result in acceptable side-effects. Neutropenia is one major side-effect of many antitumor agents, and is related to an increased risk of infection. A model capable of describing the time-course of myelosuppression from administered drug could be used in individual dose selection. In this paper we describe the transfer of a previously developed semi-mechanistic model for myelosuppression from NONMEM to a dosing tool in MS Excel, with etoposide as an example. The tool proved capable to solve a differential equation system describing the pharmacokinetics and pharmacodynamics, with estimation performance comparable to NONMEM. In the dosing tool the user provides neutrophil measures from a previous treatment course and request for the dose that results in a desired nadir in the upcoming course through a Bayesian estimation procedure. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
6. Activated Charcoal Decreases the Risk of QT Prolongation After Citalopram Overdose.
- Author
-
Isbister, Geoffrey K., Friberg, Lena E., Stokes, Barrie, Buckley, Nicholas A., Lee, Christopher, Gunja, Naren, Brown, Simon G., MacDonald, Ellen, Graudins, Andis, Holdgate, Anna, and Duffull, Stephen B.
- Abstract
Study objective: We determine whether single-dose activated charcoal (SDAC) administration after citalopram overdose reduces the proportion of patients developing abnormal QT prolongation. Methods: Data were collected retrospectively for citalopram overdose patients presenting to 8 emergency departments. Demographics, dose, coingested drugs, SDAC administration, and serial ECGs were extracted from medical records. The primary outcome was the proportion of patients who had an observed QT,RR combination at any time above an abnormal threshold, established as a predictor of torsade de pointes. We compared the proportion of patients with QT prolongation who received or did not receive SDAC. These data were analyzed within a Bayesian framework, using probabilities of abnormal QT,RR combinations with and without derived from a previous single-center study. WinBUGS was used to generate posterior estimates and credible intervals of the relative risk by combining the prior probabilities and the study data. Results: SDAC was administered on average 2.1 hours (range, 0.5 to 6.25 hours) after ingestion in 48 of 254 admissions, and abnormal QT,RR combinations occurred in 2 cases (4.2%), compared with 23 of 206 (11.2%) cases not receiving SDAC. There did not appear to be any clinically important difference in age, sex, dose, and cardiotoxic coingestants between the 2 groups. No cases of torsade de pointes occurred. The estimated relative risk of having an abnormal QT,RR combination for SDAC compared to no SDAC was 0.28 (0.06 to 0.70) (median with 2.5% and 97.5% credible limits). The probability that the relative risk was less than 1.0 was 0.99, which can be interpreted as very strong evidence in favor of a beneficial effect of SDAC. The absolute risk difference was estimated as 7.5% and the median number needed to treat as 13.3. Conclusion: SDAC may be effective in reducing the risk of a prolonged QT in patients after citalopram overdose. Current trends toward nonuse of activated charcoal should be evaluated to determine whether patients poisoned by specific agents may benefit from activated charcoal administration. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
7. Pharmacokinetic–pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model
- Author
-
Friberg, Lena E., Hassan, Saadia B., Lindhagen, Elin, Larsson, Rolf, and Karlsson, Mats O.
- Subjects
- *
PHARMACOKINETICS , *PHARMACODYNAMICS , *ANTINEOPLASTIC agents , *DRUG metabolism - Abstract
Abstract: N-(6-Chlorophenoxyhexyl)-N′-cyano-N″-4-pyridylguanidine (CHS 828) is a novel anticancer agent that shows schedule-dependent effects in vitro and in vivo, as well as in Phase I clinical trials. A rat hollow fibre model was used to investigate whether this dependency is due to pharmacokinetic and/or pharmacodynamic factors. The effect on two cell lines, MDA-MB-231 (breast cancer) and CCRF-CEM (leukaemia) were studied after CHS 828 was administered orally as a single dose or in a 5-day schedule, at different total dose levels. The 5-day schedules were associated with greater effects on both cell lines compared with single doses. A one-compartment pharmacokinetic model, with a half-life of 2.3h and a consecutive zero- and first-order process to describe dissolution and absorption, fit the concentration data. Pharmacokinetics were dose-dependent, as the fraction absorbed decreased with increasing dose. Clearance increased with accumulative exposure. Twenty hours after administration, concentrations started to increase again, probably due to coprophagy. Pharmacokinetic–pharmacodynamic models characterized the cell growth and cell kill over time and showed that schedule-dependent antitumour effects were present also when the dose-dependent pharmacokinetics were accounted for. The prolonged schedules of CHS 828 were therefore associated with greater antitumour effects than single doses of the same total exposure. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
8. Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia.
- Author
-
Aranzana-Climent, Vincent, Hughes, Diarmaid, Cao, Sha, Tomczak, Magdalena, Urbas, Malgorzata, Zabicka, Dorota, Vingsbo Lundberg, Carina, Hansen, Jon, Lindberg, Johan, Hobbie, Sven N., and Friberg, Lena E.
- Subjects
- *
GRAM-negative bacteria , *LUNG infections , *PNEUMONIA , *PSEUDOMONAS aeruginosa , *PHARMACODYNAMICS , *KLEBSIELLA pneumoniae , *BACTERICIDAL action , *ACINETOBACTER baumannii - Abstract
New drugs and methods to efficiently fight carbapenem-resistant gram-negative pathogens are sorely needed. In this study, we characterized the preclinical pharmacokinetics (PK) and pharmacodynamics of the clinical stage drug candidate apramycin in time kill and mouse lung infection models. Based on in vitro and in vivo data, we developed a mathematical model to predict human efficacy. Three pneumonia-inducing gram-negative species Acinetobacter baumannii , Pseudomonas aeruginosa , and Klebsiella pneumoniae were studied. Bactericidal kinetics were evaluated with time-kill curves; in vivo PK were studied in healthy and infected mice, with sampling in plasma and epithelial lining fluid after subcutaneous administration; in vivo efficacy was measured in a neutropenic mouse pneumonia model. A pharmacokinetic-pharmacodynamic model, integrating all the data, was developed and simulations were performed. Good lung penetration of apramycin in epithelial lining fluid (ELF) was shown (area under the curve (AUC) ELF /AUC plasma = 88%). Plasma clearance was 48% lower in lung infected mice compared to healthy mice. For two out of five strains studied, a delay in growth (∼5 h) was observed in vivo but not in vitro. The mathematical model enabled integration of lung PK to drive mouse PK and pharmacodynamics. Simulations predicted that 30 mg/kg of apramycin once daily would result in bacteriostasis in patients. Apramycin is a candidate for treatment of carbapenem-resistant gram-negative pneumonia as demonstrated in an integrated modeling framework for three bacterial species. We show that mathematical modelling is a useful tool for simultaneous inclusion of multiple data sources, notably plasma and lung in vivo PK and simulation of expected scenarios in a clinical setting, notably lung infections. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects.
- Author
-
Minichmayr, Iris K., Aranzana-Climent, Vincent, and Friberg, Lena E.
- Subjects
- *
PHARMACOKINETICS , *ANTIBIOTICS , *DRUG therapy , *PHARMACODYNAMICS , *DRUG development - Abstract
• One hundred and thirty-two publications on pharmacokinetic/pharmacodynamic (PKPD) models for time courses of antibiotic effects were reviewed. • Points to consider when developing such PKPD models are discussed. • Models describing bacterial growth, regrowth, drug effects and interactions are shown. • An interactive online table enables the review of PKPD models from 1963 to 2021. Pharmacokinetic/pharmacodynamic (PKPD) models have emerged as valuable tools for the characterization and translation of antibiotic effects, and consequently for drug development and therapy. In contrast to traditional PKPD concepts for antibiotics such as minimum inhibitory concentration and PKPD indices, PKPD models enable description of the continuous, often species- or population-dependent time course of antimicrobial effects, commonly considering mechanistic pathogen- and drug-related knowledge. This review presents a comprehensive overview of previously published PKPD models describing repeated measurements of antibiotic effects. A literature review was conducted to identify PKPD models based on: (i) antibiotic compounds; (ii) Gram-positive or Gram-negative pathogens; and (iii) in-vitro or in-vivo longitudinal colony-forming unit data. In total, 132 publications were identified that were released between 1963 and 2021, including models based on exposure to single antibiotics (n =92) and drug combinations (n =40), as well as different experimental settings (e.g. static/traditional dynamic/hollow-fibre/animal time-kill models, n =90/27/32/11). An interactive, fully searchable table summarizes the details of each model, namely variants and mechanistic elements of PKPD submodels capturing observed bacterial growth, regrowth, drug effects and interactions. Furthermore, the review highlights the main purposes of PKPD model development, including the translation of preclinical PKPD to clinical settings, and the assessment of varied dosing regimens and patient characteristics for their impact on clinical antibiotic effects. In summary, this comprehensive overview of PKPD models will assist in identifying PKPD modelling strategies to describe growth, killing, regrowth and interaction patterns for pathogen–antibiotic combinations over time, and ultimately facilitate model-informed antibiotic translation, dosing and drug development. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections.
- Author
-
Nutman, Amir, Temkin, Elizabeth, Lellouche, Jonathan, Rakovitsky, Nadya, Hameir, Amichay, Daikos, George, Durante-Mangoni, Emanuele, Pavleas, Ioannis, Dishon, Yael, Petersiel, Neta, Yahav, Dafna, Eliakim, Noa, Bernardo, Mariano, Iossa, Domenico, Friberg, Lena E., Theuretzbacher, Ursula, Leibovici, Leonard, Paul, Mical, and Carmeli, Yehuda
- Subjects
- *
CARBAPENEM-resistant bacteria , *ACINETOBACTER baumannii , *NOSOCOMIAL infections , *TREATMENT failure , *URINARY tract infections , *INTENSIVE care units - Abstract
Mortality among patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections varies between studies. We examined whether in vivo fitness of CRAB strains is associated with clinical outcomes in patients with CRAB infections. Isolates were collected from patients enrolled in the AIDA trial with hospital-acquired pneumonia, bloodstream infections and/or urinary tract infections caused by CRAB. The primary outcome was 14-day clinical failure, defined as failure to meet all criteria: alive; haemodynamically stable; improved or stable Sequential Organ Failure Assessment (SOFA) score; improved or stable oxygenation; and microbiological cure of bacteraemia. The secondary outcome was 14-day mortality. We tested in vivo growth using a neutropenic murine thigh infection model. Fitness was defined based on the CFU count 24 hours after injection of an inoculum of 105 CFU. We used mixed-effects logistic regression to test the association between fitness and the two outcomes. The sample included 266 patients; 215 (80.8%) experienced clinical failure. CRAB fitness ranged from 5.23 to 10.08 log CFU/g. The odds of clinical failure increased by 62% for every 1-log CFU/g increase in fitness (OR 1.62, 95% CI 1.04–2.52). After adjusting for age, Charlson score, SOFA score and acquisition in the intensive care unit, fitness remained significant (adjusted OR 1.63, 95% CI 1.03–2.59). CRAB fitness had a similar effect on 14-day mortailty, although the association was not statistically significant (OR 1.56, 95% CI 0.95–2.57). It became significant after adjusting for age, Charlson score, SOFA score and recent surgery (adjusted OR 1.88, 95% CI 1.09–3.25). In vivo CRAB fitness was associated with clinical failure in patients with CRAB infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice.
- Author
-
Becker, Katja, Aranzana-Climent, Vincent, Cao, Sha, Nilsson, Anna, Shariatgorji, Reza, Haldimann, Klara, Platzack, Björn, Hughes, Diarmaid, Andrén, Per E., Böttger, Erik C., Friberg, Lena E., and Hobbie, Sven N.
- Subjects
- *
LUNG infections , *ACINETOBACTER infections , *ACINETOBACTER baumannii , *CARBAPENEM-resistant bacteria , *LUNGS , *GENOTYPES - Abstract
Novel therapeutics are urgently required for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) causing critical infections with high mortality. Here we assessed the therapeutic potential of the clinical-stage drug candidate EBL-1003 (crystalline free base of apramycin) in the treatment of CRAB lung infections. The genotypic and phenotypic susceptibility of CRAB clinical isolates to aminoglycosides and colistin was assessed by database mining and broth microdilution. The therapeutic potential was assessed by target attainment simulations on the basis of time–kill kinetics, a murine lung infection model, comparative pharmacokinetic analysis in plasma, epithelial lining fluid (ELF) and lung tissue, and pharmacokinetic/pharmacodynamic (PKPD) modelling. Resistance gene annotations of 5451 CRAB genomes deposited in the National Database of Antibiotic Resistant Organisms (NDARO) suggested >99.9% of genotypic susceptibility to apramycin. Low susceptibility to standard-of-care aminoglycosides and high susceptibility to EBL-1003 were confirmed by antimicrobial susceptibility testing of 100 A. baumannii isolates. Time–kill experiments and a mouse lung infection model with the extremely drug-resistant CRAB strain AR Bank #0282 resulted in rapid 4-log CFU reduction both in vitro and in vivo. A single dose of 125 mg/kg EBL-1003 in CRAB-infected mice resulted in an AUC of 339 h × μg/mL in plasma and 299 h × μg/mL in ELF, suggesting a lung penetration of 88%. PKPD simulations suggested a previously predicted dose of 30 mg/kg in patients (creatinine clearance (CLCr) = 80 mL/min) to result in >99% probability of –2 log target attainment for MICs up to 16 μg/mL. This study provides proof of concept for the efficacy of EBL-1003 in the treatment of CRAB lung infections. Broad in vitro coverage, rapid killing, potent in vivo efficacy, and a high probability of target attainment render EBL-1003 a strong therapeutic candidate for a priority pathogen for which treatment options are very limited. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infections.
- Author
-
Thorsted, Anders, Nielsen, Elisabet I., and Friberg, Lena E.
- Subjects
- *
TREATMENT effectiveness , *BACTERIAL diseases , *IMMUNE response , *PHARMACODYNAMICS , *BIOMARKERS - Abstract
This mini-review discusses the pharmacodynamics of immune-related biomarkers in the area of bacterial infectious diseases that could be of interest from a pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/PD) perspective in the evaluation of treatment effects. The host response to an infection is often poorly defined both in preclinical assessments and in clinical practice when it comes to characterisation of PK and PK/PD relationships. Through population modelling, the time courses and variability of immune response variables can be quantified. Incorporation of such biomarker information into PK and PK/PD models may guide the evaluation of individual response to treatment (right antibiotic, more antibiotic, less antibiotic) and when to stop treatment. Furthermore, translation of results from preclinical systems to clinical scenarios may be improved with the incorporation of biomarker information. Potential biomarkers for these purposes are discussed and a few modelling examples are provided. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. How preclinical infection models help define antibiotic doses in the clinic.
- Author
-
Tängdén, Thomas, Lundberg, Carina Vingsbo, Friberg, Lena E., and Huttner, Angela
- Subjects
- *
ANIMAL models in research , *EXPERIMENTAL design , *LUNG infections , *PHARMACOKINETICS , *POPULATION - Abstract
• In vitro studies are essential for the evaluation of new antibiotic treatments. • Animal models are an important link between in vitro data and clinical testing. • Market authorization and dosing guidelines rely on preclinical pharmacokinetic/pharmacodynamic (PK/PD) studies. • Mathematical modeling can optimize study design and translation of preclinical data. • More clinical trials for optimal dosing are warranted but are difficult to perform. Appropriate dosing of antibiotics is key in the treatment of bacterial infections to ensure clinical efficacy while avoiding toxic drug concentrations and minimizing emergence of resistance. As collection of sufficient clinical evidence is difficult for specific patient populations, infection types and pathogens, market authorization, dosing strategies and recommendations often rely on data obtained from in vitro and animal experiments. The aim of this review is to provide an overview of commonly used preclinical infection models, including their strengths and limitations. In vitro, static and dynamic time-kill experiments are the most frequently used methods for assessing pharmacokinetic/pharmacodynamic (PK/PD) associations. Limitations of in vitro models include the inability to account for the effects of the immune system, and uncertainties in clinically relevant bacterial concentrations, growth conditions and the implications of emerging resistant bacterial populations during experiments. Animal experiments, most commonly murine lung and thigh infections models, are considered a necessary link between in vitro data and the clinical situation. However, there are differences in pathophysiology, immunology, and PK between species. Mathematical modeling in which preclinical data are integrated with human population PK can facilitate translation of preclinical data to the patient's clinical situation. Moreover, PK/PD modeling and simulations can help in the design of clinical trials aiming to establish optimal dosing regimens to improve patient outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes.
- Author
-
Nutman, Amir, Lellouche, Jonathan, Temkin, Elizabeth, Daikos, George, Skiada, Anna, Durante-Mangoni, Emanuele, Dishon-Benattar, Yael, Bitterman, Roni, Yahav, Dafna, Daitch, Vered, Bernardo, Mariano, Iossa, Domenico, Zusman, Oren, Friberg, Lena E., Mouton, Johan W., Theuretzbacher, Ursula, Leibovici, Leonard, Paul, Mical, and Carmeli, Yehuda
- Subjects
- *
MEROPENEM , *CARBAPENEMS , *COLISTIN , *CARBAPENEM-resistant bacteria , *ACINETOBACTER baumannii , *RANDOMIZED controlled trials - Abstract
In vitro models showing synergism between polymyxins and carbapenems support combination treatment for carbapenem-resistant Gram-negative (CRGN) infections. We tested the association between the presence of in vitro synergism and clinical outcomes in patients treated with colistin plus meropenem. This was a secondary analysis of AIDA, a randomized controlled trial comparing colistin with colistin–meropenem for severe CRGN infections. We tested in vitro synergism using a checkerboard assay. Based on the fractional inhibitory concentration (ΣFIC) index for each colistin–meropenem combination, we categorized results as synergistic, antagonistic or additive/indifferent. The primary outcome was clinical failure at 14 days. Secondary outcomes were 14- and 28-day mortality and microbiological failure. The sample included 171 patients with infections caused by carbapenem-resistant Acinetobacter baumannii (n = 131), Enterobacteriaceae (n = 37) and Pseudomonas aeuruginosa (n = 3). In vitro testing showed synergism for 73 isolates, antagonism for 20 and additivism/indifference for 78. In patients who received any colistin plus meropenem, clinical failure at 14 days was 59/78 (75.6%) in the additivism/indifference group (reference category), 54/73 (74.0%) in the synergism group (adjusted odds ratio (aOR) 0.76, 95% CI 0.31–1.83), and 11/20 (55%) in the antagonism group (aOR 0.77, 95% CI 0.22–2.73). There was no significant difference between groups for any secondary outcome. Comparing the synergism group to patients treated with colistin monotherapy, synergism was not protective against 14-day clinical failure (aOR 0.52, 95% CI 0.26–1.04) or 14-day mortality (aOR1.09, 95% CI 0.60–1.96). In vitro synergism between colistin and meropenem via checkerboard method did not translate into clinical benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy.
- Author
-
Bue, Mats, Sou, Tomás, Okkels, Anna Sophie L., Hanberg, Pelle, Thorsted, Anders, Friberg, Lena E., Andersson, Torben L., Öbrink-Hansen, Kristina, and Christensen, Steffen
- Subjects
- *
PHARMACOKINETICS , *PIPERACILLIN , *ACUTE kidney failure , *PSEUDOMONAS aeruginosa , *CRITICALLY ill , *RENAL replacement therapy - Abstract
• Population pharmacokinetics of piperacillin in subcutaneous tissue and plasma in patients treated with continuous renal replacement therapy (CRRT). • Subcutaneous tissue concentrations were lower than plasma concentrations. • If an aggressive target of 100% f T > 4 × MIC (Pseudomonas aeruginosa , 16 mg/l) is adopted, continuous infusion is needed. Piperacillin is a β-lactam antimicrobial frequently used in critically ill patients with acute kidney injury treated with continuous renal replacement therapy (CRRT). However, data regarding piperacillin tissue concentrations in this patient population are limited. A prospective observational study was conducted of free piperacillin concentrations during a single 8-h dosing interval in plasma (8 samples) and subcutaneous tissue (SCT) (13 samples), in 10 patients treated with CRRT following piperacillin 4 g given every 8 h as intermittent administration over 3 min. A population pharmacokinetic model was developed using NONMEM 7.4.3, to simulate alternative administration modes and dosing regimens. SCT concentrations were obtained using microdialysis. Piperacillin concentrations were compared to the clinical breakpoint minimum inhibitory concentration (MIC) for Pseudomonas aeruginosa (16 mg/l), with evaluation of the following pharmacokinetic/pharmacodynamics targets: 50% f T > 1 × MIC, 100% f T > 1 × MIC, and 100% f T > 4 × MIC. SCT concentrations were generally lower than plasma concentrations. For the target of 50% free time (f T) > 1 × MIC and 100% f T > 1 × MIC, piperacillin 4 g every 8 h resulted in probability of target attainment (PTA) >90% in both plasma and SCT. PTA > 90% for the target of 100% f T > 4 × MIC was only achieved for continuous infusion. Piperacillin 4 g every 8 h is likely to provide sufficient exposure in both plasma and SCT to treat P.aeruginosa infections in critically ill patients on CRRT, given that targets of 50% f T > 1 × MIC or 100% f T > 1 × MIC are adequate. However, if a more aggressive target of 100% f T > 4 × MIC is adopted, continuous infusion is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection.
- Author
-
Sou, Tomás, Kukavica-Ibrulj, Irena, Soukarieh, Fadi, Halliday, Nigel, Levesque, Roger C., Williams, Paul, Stocks, Michael, Cámara, Miguel, Friberg, Lena E., and Bergström, Christel A.S.
- Subjects
- *
DRUG development , *PSEUDOMONAS aeruginosa infections , *DRUG delivery systems , *PUBLIC health , *QUORUM sensing - Abstract
Abstract Antibiotic resistance is a major public health threat worldwide. In particular, about 80% of cystic fibrosis patients have chronic Pseudomonas aeruginosa (PA) lung infection resistant to many current antibiotics. We are therefore developing a novel class of antivirulence agents, quorum sensing inhibitors (QSIs), which inhibit biofilm formation and sensitize PA to antibiotic treatments. For respiratory conditions, targeted delivery to the lung could achieve higher local concentrations with reduced risk of adverse systemic events. In this study, we report the pharmacokinetics of 3 prototype QSIs after pulmonary delivery, and the simultaneous analysis of the drug concentration-time profiles from bronchoalveolar lavage, lung homogenate and plasma samples, using a pharmacometric modeling approach. In addition to facilitating the direct comparison and selection of drug candidates, the developed model was used for dosing simulation studies to predict in vivo exposure following different dosing scenarios. The results show that systemic clearance has limited impact on local drug exposure in the lung after pulmonary delivery. Therefore, we suggest that novel QSIs designed for pulmonary delivery as targeted treatments for respiratory conditions should ideally have a long residence time in the lung for local efficacy with rapid clearance after systemic absorption for reduced risk of systemic adverse events. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli.
- Author
-
Khan, David D., Lagerbäck, Pernilla, Malmberg, Christer, Kristoffersson, Anders N., Wistrand-Yuen, Erik, Sha, Cao, Cars, Otto, Andersson, Dan I., Hughes, Diarmaid, Nielsen, Elisabet I., and Friberg, Lena E.
- Subjects
- *
CIPROFLOXACIN , *DRUG resistance in bacteria , *COMPETITION (Biology) , *ESCHERICHIA coli mutation , *PHARMACOKINETICS , *COLONY-forming units assay , *ESCHERICHIA coli - Abstract
Predicting competition between antibiotic-susceptible wild-type (WT) and less susceptible mutant (MT) bacteria is valuable for understanding how drug concentrations influence the emergence of resistance. Pharmacokinetic/pharmacodynamic (PK/PD) models predicting the rate and extent of takeover of resistant bacteria during different antibiotic pressures can thus be a valuable tool in improving treatment regimens. The aim of this study was to evaluate a previously developed mechanism-based PK/PD model for its ability to predict in vitro mixed-population experiments with competition between Escherichia coli (E. coli) WT and three well-defined E. coli resistant MTs when exposed to ciprofloxacin. Model predictions for each bacterial strain and ciprofloxacin concentration were made for in vitro static and dynamic time–kill experiments measuring CFU (colony forming units)/mL up to 24 h with concentrations close to or below the minimum inhibitory concentration (MIC), as well as for serial passage experiments with concentrations well below the MIC measuring ratios between the two strains with flow cytometry. The model was found to reasonably well predict the initial bacterial growth and killing of most static and dynamic time–kill competition experiments without need for parameter re-estimation. With parameter re-estimation of growth rates, an adequate fit was also obtained for the 6-day serial passage competition experiments. No bacterial interaction in growth was observed. This study demonstrates the predictive capacity of a PK/PD model and further supports the application of PK/PD modelling for prediction of bacterial kill in different settings, including resistance selection. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia.
- Author
-
Gkoufa, Aikaterini, Sou, Tomás, Karaiskos, Ilias, Routsi, Christina, Lin, Yu-Wei, Psichogiou, Mina, Zakynthinos, Spyros, Giamarellou, Helen, Li, Jian, and Friberg, Lena E.
- Subjects
- *
VENTILATOR-associated pneumonia , *COLISTIN , *LIQUID chromatography-mass spectrometry , *PHARMACOKINETICS - Abstract
• CMS and formed colistin were notably higher (∼100- to 600-fold) in ELF than plasma after nebulisation of 3 and 5 MIU CMS. • Free ELF concentrations of formed colistin were approximately 1- to 10-fold higher than the median MIC. • Concomitant intravenous administration of CMS has minimal impact on formed colistin concentrations in ELF. • Plasma formed colistin concentrations after nebulisation were constantly lower than those associated with nephrotoxicity. There has been accumulating interest in nebulised colistin methanesulfonate (CMS) for the treatment of ventilator-associated pneumonia (VAP). In this study, pulmonary and systemic pharmacokinetics following nebulisation of CMS at a dose of 3 MIU and 5 MIU, using a vibrating mesh nebuliser, for VAP caused by extensively drug-resistant Gram-negative pathogens was assessed. Blood samples and mini-bronchoalveolar lavage (mini-BAL) was performed post-dose at 1, 4 and 8 h. Concentrations of CMS and formed colistin in mini-BAL and plasma were determined by liquid chromatography–tandem mass spectrometry, and pharmacokinetic analysis was conducted using a population approach. The study population included three groups (n = 10 per group): (A) intravenous CMS and concomitantly nebulised CMS at a dose of 3 MIU (30 min duration); (B) nebulised CMS at a dose of 3 MIU (30 min duration) as monotherapy; and (C) nebulised CMS 5 MIU (45 min duration) as monotherapy. Mean plasma formed colistin concentrations were <1 mg/L following CMS nebulisation as monotherapy (groups B and C). Predicted trough concentrations of formed colistin in the epithelial lining fluid (ELF) following 24-h dosing of 3 MIU and 5 MIU nebulised CMS were 120.4 mg/L and 200.7 mg/L, respectively. The model predicted that concomitant intravenous CMS (group A) had minimal impact on the formed colistin concentration in ELF. This study demonstrated high ELF formed colistin concentrations following nebulised CMS (constantly above colistin MICs), while plasma concentrations were lower than those associated with nephrotoxicity. Our results provide important information for optimisation of nebulised colistin therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Acute organophosphorus poisoning in humans: A PK model for chlorpyrifos
- Author
-
Anderson, Jacqueline M., Petersson, Klas J., Friberg, Lena E., Worek, Franz, Thiermann, Horst, and Buckley, Nicholas A.
- Published
- 2012
- Full Text
- View/download PDF
20. Modelling the genesis and treatment of cancer: The potential role of physiologically based pharmacodynamics
- Author
-
Steimer, Jean-Louis, Dahl, Svein G., De Alwis, Dinesh P., Gundert-Remy, Ursula, Karlsson, Mats O., Martinkova, Jirina, Aarons, Leon, Ahr, Hans-Jürgen, Clairambault, Jean, Freyer, Gilles, Friberg, Lena E., Kern, Steven E., Kopp-Schneider, Annette, Ludwig, Wolf-Dieter, Nicolao, Giuseppe De, Rocchetti, Maurizio, and Troconiz, Iñaki F.
- Subjects
- *
CANCER treatment , *CANCER genetics , *PHARMACODYNAMICS , *MOLECULAR biology , *PROTEIN kinases , *TUMOR growth , *DRUG toxicity - Abstract
Abstract: Physiologically based modelling of pharmacodynamics/toxicodynamics requires an a priori knowledge on the underlying mechanisms causing toxicity or causing the disease. In the context of cancer, the objective of the expert meeting was to discuss the molecular understanding of the disease, modelling approaches used so far to describe the process, preclinical models of cancer treatment and to evaluate modelling approaches developed based on improved knowledge. Molecular events in cancerogenesis can be detected using ‘omics’ technology, a tool applied in experimental carcinogenesis, but also for diagnostics and prognosis. The molecular understanding forms the basis for new drugs, for example targeting protein kinases specifically expressed in cancer. At present, empirical preclinical models of tumour growth are in great use as the development of physiological models is cost and resource intensive. Although a major challenge in PKPD modelling in oncology patients is the complexity of the system, based in part on preclinical models, successful models have been constructed describing the mechanism of action and providing a tool to establish levels of biomarker associated with efficacy and assisting in defining biologically effective dose range selection for first dose in man. To follow the concentration in the tumour compartment enables to link kinetics and dynamics. In order to obtain a reliable model of tumour growth dynamics and drug effects, specific aspects of the modelling of the concentration–effect relationship in cancer treatment that need to be accounted for include: the physiological/circadian rhythms of the cell cycle; the treatment with combinations and the need to optimally choose appropriate combinations of the multiple agents to study; and the schedule dependence of the response in the clinical situation. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
21. Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data.
- Author
-
Zhao, Chenyan, Wistrand-Yuen, Pikkei, Lagerbäck, Pernilla, Tängdén, Thomas, Nielsen, Elisabet I., and Friberg, Lena E.
- Subjects
- *
POLYMYXIN B , *KLEBSIELLA pneumoniae , *MINOCYCLINE , *MULTIDRUG-resistant tuberculosis , *PHARMACOKINETICS , *DRUG resistance - Abstract
• Minocycline and polymyxin B in combination showed net killing of a multidrug-resistant Klebsiella pneumoniae isolate. • Bacterial killing and drug interaction were successfully quantified in a pharmacokinetic/pharmacodynamic (PKPD) model. • The minocycline effect was enhanced by polymyxin B, but not vice versa. • A clinical benefit of the combination was suggested also when human PK was considered. Lack of effective treatment for multidrug-resistant Klebsiella pneumoniae (MDR-Kp) necessitates finding and optimising combination therapies of old antibiotics. The aims of this study were to quantify the combined effect of polymyxin B and minocycline by building an in silico semi-mechanistic pharmacokinetic/pharmacodynamic (PKPD) model and to predict bacterial kinetics when exposed to the drugs alone and in combination at clinically achievable unbound drug concentration–time profiles. A clinical K. pneumoniae strain resistant to polymyxin B [minimum inhibitory concentration (MIC) = 16 mg/L] and minocycline (MIC = 16 mg/L) was selected for extensive in vitro static time–kill experiments. The strain was exposed to concentrations of 0.0625–48 × MIC, with seven samples taken per experiment for viable counts during 0–28 h. These observations allowed the development of the PKPD model. The final PKPD model included drug-induced adaptive resistance for both drugs. Both the minocycline-induced bacterial killing and resistance onset rate constants were increased when polymyxin B was co-administered, whereas polymyxin B parameters were unaffected. Predictions at clinically used dosages from the developed PKPD model showed no or limited antibacterial effect with monotherapy, whilst combination therapy kept bacteria below the starting inoculum for >20 h at high dosages [polymyxin B 2.5 mg/kg + 1.5 mg/kg every 12 h (q12h); minocycline 400 mg + 200 mg q12h, loading + maintenance doses]. This study suggests that polymyxin B and minocycline in combination may be of clinical benefit in the treatment of infections by MDR-Kp and for isolates that are non-susceptible to either drug alone. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.